25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Dermapharm Holding SE
Buy, Hold or Sell?

Let's analyze Dermapharm Holding SE together

I guess you are interested in Dermapharm Holding SE. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Dermapharm Holding SE. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Dermapharm Holding SE

I send you an email if I find something interesting about Dermapharm Holding SE.

1. Quick Overview

1.1. Quick analysis of Dermapharm Holding SE (30 sec.)










1.2. What can you expect buying and holding a share of Dermapharm Holding SE? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€10.33
Expected worth in 1 year
€10.99
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
€0.65
Return On Investment
1.8%

For what price can you sell your share?

Current Price per Share
€36.00
Expected price per share
€35.70 - €38.43
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Dermapharm Holding SE (5 min.)




Live pricePrice per Share (EOD)
€36.00

2.2. Growth of Dermapharm Holding SE (5 min.)




Is Dermapharm Holding SE growing?

Current yearPrevious yearGrowGrow %
How rich?$588.2m$565.6m$24.6m4.2%

How much money is Dermapharm Holding SE making?

Current yearPrevious yearGrowGrow %
Making money$21.9m$32.3m-$10.4m-47.6%
Net Profit Margin7.1%10.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Dermapharm Holding SE (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Dermapharm Holding SE?

Welcome investor! Dermapharm Holding SE's management wants to use your money to grow the business. In return you get a share of Dermapharm Holding SE.

First you should know what it really means to hold a share of Dermapharm Holding SE. And how you can make/lose money.

Speculation

The Price per Share of Dermapharm Holding SE is €36.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Dermapharm Holding SE.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Dermapharm Holding SE, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €10.33. Based on the TTM, the Book Value Change Per Share is €0.16 per quarter. Based on the YOY, the Book Value Change Per Share is €0.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Dermapharm Holding SE.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.340.9%0.411.1%0.601.7%0.641.8%0.641.8%
Usd Book Value Change Per Share-0.60-1.7%0.170.5%0.320.9%0.912.5%0.912.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.60-1.7%0.170.5%0.320.9%0.912.5%0.912.5%
Usd Price Per Share38.16-39.83-41.64-51.55-51.55-
Price to Earnings Ratio28.14--38.14--7.39--6.93--6.93-
Price-to-Total Gains Ratio-63.16--3,158.17-28.97--1,032.08--1,032.08-
Price to Book Ratio3.49-3.65-3.98-5.16-5.16-
Price-to-Total Gains Ratio-63.16--3,158.17-28.97--1,032.08--1,032.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share38.0556
Number of shares26
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.170.91
Usd Total Gains Per Share0.170.91
Gains per Quarter (26 shares)4.4723.67
Gains per Year (26 shares)17.8894.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1018809585
2036260189180
3054440284275
4072620379370
5089800473465
60107980568560
701251160663655
801431340757750
901611520852845
1001791700947940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%10.02.00.083.3%10.02.00.083.3%10.02.00.083.3%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%8.04.00.066.7%8.04.00.066.7%8.04.00.066.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share2.02.00.050.0%8.04.00.066.7%8.04.00.066.7%8.04.00.066.7%8.04.00.066.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Dermapharm Holding SE compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.5720.163-451%0.307-286%0.861-166%0.861-166%
Book Value Per Share--10.33510.3730%9.939+4%9.738+6%9.738+6%
Current Ratio--1.5811.651-4%2.329-32%2.276-31%2.276-31%
Debt To Asset Ratio--0.7480.743+1%0.690+8%0.698+7%0.698+7%
Debt To Equity Ratio--2.9932.918+3%2.330+28%2.403+25%2.403+25%
Dividend Per Share----0%-0%-0%-0%
Eps--0.3210.386-17%0.569-44%0.605-47%0.605-47%
Free Cash Flow Per Share--0.2110.676-69%1.241-83%0.934-77%0.934-77%
Free Cash Flow To Equity Per Share--0.2110.676-69%1.241-83%0.934-77%0.934-77%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap--1943624000.0002028691200.000-4%2120744140.000-8%2625772313.333-26%2625772313.333-26%
Net Profit Margin--0.0620.071-13%0.106-42%0.121-49%0.121-49%
Operating Margin----0%-0%-0%-0%
Operating Ratio--1.2301.192+3%1.146+7%1.140+8%1.140+8%
Pb Ratio3.4830%3.4933.645-4%3.976-12%5.159-32%5.159-32%
Pe Ratio28.0610%28.139-38.143+236%-7.392+126%-6.933+125%-6.933+125%
Price Per Share36.0000%36.10037.680-4%39.390-8%48.770-26%48.770-26%
Price To Free Cash Flow Ratio42.6700%42.78820.030+114%57.596-26%33.387+28%33.387+28%
Price To Total Gains Ratio-62.985+0%-63.160-3158.165+4900%28.970-318%-1032.077+1534%-1032.077+1534%
Quick Ratio--0.2680.313-14%0.481-44%0.452-41%0.452-41%
Return On Assets--0.0080.010-18%0.019-59%0.021-62%0.021-62%
Return On Equity--0.0310.037-15%0.057-45%0.064-51%0.064-51%
Total Gains Per Share---0.5720.163-451%0.307-286%0.861-166%0.861-166%
Usd Book Value--588202153.000590366300.9750%565678523.300+4%554253034.133+6%554253034.133+6%
Usd Book Value Change Per Share---0.6040.172-451%0.325-286%0.910-166%0.910-166%
Usd Book Value Per Share--10.92510.9650%10.507+4%10.294+6%10.294+6%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.3390.408-17%0.602-44%0.640-47%0.640-47%
Usd Free Cash Flow--12004427.60038475268.700-69%70639650.400-83%53161647.092-77%53161647.092-77%
Usd Free Cash Flow Per Share--0.2230.715-69%1.312-83%0.987-77%0.987-77%
Usd Free Cash Flow To Equity Per Share--0.2230.715-69%1.312-83%0.987-77%0.987-77%
Usd Market Cap--2054604930.4002144529467.520-4%2241838630.394-8%2775703912.425-26%2775703912.425-26%
Usd Price Per Share38.0560%38.16139.832-4%41.639-8%51.555-26%51.555-26%
Usd Profit--18254002.80021944603.175-17%32390336.825-44%34438908.533-47%34438908.533-47%
Usd Revenue--295778694.200299095081.175-1%300148481.325-1%286631079.350+3%286631079.350+3%
Usd Total Gains Per Share---0.6040.172-451%0.325-286%0.910-166%0.910-166%
 EOD+5 -1MRQTTM+3 -29YOY+6 -265Y+7 -2510Y+7 -25

3.3 Fundamental Score

Let's check the fundamental score of Dermapharm Holding SE based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1528.061
Price to Book Ratio (EOD)Between0-13.483
Net Profit Margin (MRQ)Greater than00.062
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.268
Current Ratio (MRQ)Greater than11.581
Debt to Asset Ratio (MRQ)Less than10.748
Debt to Equity Ratio (MRQ)Less than12.993
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.008
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Dermapharm Holding SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose36.000
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Dermapharm Holding SE

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Dermapharm Holding SE earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Dermapharm Holding SE to the  industry mean.
  • A Net Profit Margin of 6.2% means that €0.06 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Dermapharm Holding SE:

  • The MRQ is 6.2%. The company is making a profit. +1
  • The TTM is 7.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.2%TTM7.1%-1.0%
TTM7.1%YOY10.6%-3.4%
TTM7.1%5Y12.1%-4.9%
5Y12.1%10Y12.1%0.0%
4.3.1.2. Return on Assets

Shows how efficient Dermapharm Holding SE is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Dermapharm Holding SE to the  industry mean.
  • 0.8% Return on Assets means that Dermapharm Holding SE generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Dermapharm Holding SE:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM1.0%-0.2%
TTM1.0%YOY1.9%-0.9%
TTM1.0%5Y2.1%-1.1%
5Y2.1%10Y2.1%0.0%
4.3.1.3. Return on Equity

Shows how efficient Dermapharm Holding SE is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Dermapharm Holding SE to the  industry mean.
  • 3.1% Return on Equity means Dermapharm Holding SE generated €0.03 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Dermapharm Holding SE:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.7%-0.5%
TTM3.7%YOY5.7%-2.0%
TTM3.7%5Y6.4%-2.7%
5Y6.4%10Y6.4%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Dermapharm Holding SE.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Dermapharm Holding SE is operating .

  • Measures how much profit Dermapharm Holding SE makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Dermapharm Holding SE to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Dermapharm Holding SE:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Dermapharm Holding SE is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.23 means that the operating costs are €1.23 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Dermapharm Holding SE:

  • The MRQ is 1.230. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.192. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.230TTM1.192+0.038
TTM1.192YOY1.146+0.046
TTM1.1925Y1.140+0.052
5Y1.14010Y1.1400.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Dermapharm Holding SE.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Dermapharm Holding SE is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 1.58 means the company has €1.58 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Dermapharm Holding SE:

  • The MRQ is 1.581. The company is able to pay all its short-term debts. +1
  • The TTM is 1.651. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.581TTM1.651-0.069
TTM1.651YOY2.329-0.678
TTM1.6515Y2.276-0.625
5Y2.27610Y2.2760.000
4.4.3.2. Quick Ratio

Measures if Dermapharm Holding SE is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Dermapharm Holding SE to the  industry mean.
  • A Quick Ratio of 0.27 means the company can pay off €0.27 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Dermapharm Holding SE:

  • The MRQ is 0.268. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.313. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.268TTM0.313-0.045
TTM0.313YOY0.481-0.169
TTM0.3135Y0.452-0.140
5Y0.45210Y0.4520.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Dermapharm Holding SE.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Dermapharm Holding SE assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Dermapharm Holding SE to industry mean.
  • A Debt to Asset Ratio of 0.75 means that Dermapharm Holding SE assets are financed with 74.8% credit (debt) and the remaining percentage (100% - 74.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Dermapharm Holding SE:

  • The MRQ is 0.748. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.743. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.748TTM0.743+0.005
TTM0.743YOY0.690+0.053
TTM0.7435Y0.698+0.046
5Y0.69810Y0.6980.000
4.5.4.2. Debt to Equity Ratio

Measures if Dermapharm Holding SE is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Dermapharm Holding SE to the  industry mean.
  • A Debt to Equity ratio of 299.3% means that company has €2.99 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Dermapharm Holding SE:

  • The MRQ is 2.993. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.918. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.993TTM2.918+0.075
TTM2.918YOY2.330+0.587
TTM2.9185Y2.403+0.515
5Y2.40310Y2.4030.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Dermapharm Holding SE generates.

  • Above 15 is considered overpriced but always compare Dermapharm Holding SE to the  industry mean.
  • A PE ratio of 28.14 means the investor is paying €28.14 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Dermapharm Holding SE:

  • The EOD is 28.061. Based on the earnings, the company is overpriced. -1
  • The MRQ is 28.139. Based on the earnings, the company is overpriced. -1
  • The TTM is -38.143. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD28.061MRQ28.139-0.078
MRQ28.139TTM-38.143+66.282
TTM-38.143YOY-7.392-30.751
TTM-38.1435Y-6.933-31.210
5Y-6.93310Y-6.9330.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Dermapharm Holding SE:

  • The EOD is 42.670. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 42.788. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 20.030. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD42.670MRQ42.788-0.119
MRQ42.788TTM20.030+22.759
TTM20.030YOY57.596-37.566
TTM20.0305Y33.387-13.358
5Y33.38710Y33.3870.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Dermapharm Holding SE is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 3.49 means the investor is paying €3.49 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Dermapharm Holding SE:

  • The EOD is 3.483. Based on the equity, the company is fair priced.
  • The MRQ is 3.493. Based on the equity, the company is fair priced.
  • The TTM is 3.645. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.483MRQ3.493-0.010
MRQ3.493TTM3.645-0.152
TTM3.645YOY3.976-0.331
TTM3.6455Y5.159-1.514
5Y5.15910Y5.1590.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets2,207,102
Total Liabilities1,650,672
Total Stockholder Equity551,556
 As reported
Total Liabilities 1,650,672
Total Stockholder Equity+ 551,556
Total Assets = 2,207,102

Assets

Total Assets2,207,102
Total Current Assets695,139
Long-term Assets1,511,963
Total Current Assets
Cash And Cash Equivalents 165,762
Short-term Investments 5,979
Net Receivables 111,795
Inventory 350,718
Other Current Assets 59,448
Total Current Assets  (as reported)695,139
Total Current Assets  (calculated)693,702
+/- 1,437
Long-term Assets
Property Plant Equipment 322,470
Goodwill 578,479
Intangible Assets 528,083
Long-term Assets  (as reported)1,511,963
Long-term Assets  (calculated)1,429,032
+/- 82,931

Liabilities & Shareholders' Equity

Total Current Liabilities439,583
Long-term Liabilities1,211,089
Total Stockholder Equity551,556
Total Current Liabilities
Accounts payable 93,174
Other Current Liabilities 91,704
Total Current Liabilities  (as reported)439,583
Total Current Liabilities  (calculated)184,878
+/- 254,705
Long-term Liabilities
Long-term Liabilities Other 13,583
Long-term Liabilities  (as reported)1,211,089
Long-term Liabilities  (calculated)13,583
+/- 1,197,506
Total Stockholder Equity
Retained Earnings 380,731
Total Stockholder Equity (as reported)551,556
Total Stockholder Equity (calculated)380,731
+/- 170,825
Other
Capital Stock53,840
Common Stock Shares Outstanding 53,840
Net Invested Capital 551,556
Net Working Capital 255,556



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
1,340,489
1,406,969
1,461,323
1,416,653
1,451,426
1,412,836
2,168,013
2,113,521
2,159,323
2,160,673
2,172,986
2,207,102
2,207,1022,172,9862,160,6732,159,3232,113,5212,168,0131,412,8361,451,4261,416,6531,461,3231,406,9691,340,489
   > Total Current Assets 
462,453
519,222
504,301
502,066
543,213
533,947
676,288
602,190
627,543
630,496
648,873
695,139
695,139648,873630,496627,543602,190676,288533,947543,213502,066504,301519,222462,453
       Cash And Cash Equivalents 
118,682
160,319
127,547
83,775
130,597
149,918
213,149
110,778
117,428
158,794
117,354
165,762
165,762117,354158,794117,428110,778213,149149,918130,59783,775127,547160,319118,682
       Short-term Investments 
12,372
11,742
4,971
14,883
15,287
11,440
13,720
23,510
25,190
783
3,840
5,979
5,9793,84078325,19023,51013,72011,44015,28714,8834,97111,74212,372
       Net Receivables 
82,057
72,517
91,332
112,187
107,524
96,715
105,468
109,892
123,440
90,935
124,814
111,795
111,795124,81490,935123,440109,892105,46896,715107,524112,18791,33272,51782,057
       Inventory 
238,486
240,535
268,218
272,847
275,174
251,822
315,369
326,925
333,182
317,406
337,482
350,718
350,718337,482317,406333,182326,925315,369251,822275,174272,847268,218240,535238,486
       Other Current Assets 
10,498
2,447
12,219
18,359
14,591
3,604
25,582
27,741
24,655
10,926
64,891
59,448
59,44864,89110,92624,65527,74125,5823,60414,59118,35912,2192,44710,498
   > Long-term Assets 
878,036
887,747
957,022
914,587
908,212
878,890
1,491,726
1,511,331
1,531,780
1,530,176
1,524,113
1,511,963
1,511,9631,524,1131,530,1761,531,7801,511,3311,491,726878,890908,212914,587957,022887,747878,036
       Property Plant Equipment 
0
0
0
0
229,516
225,673
271,439
298,050
326,397
330,771
328,256
322,470
322,470328,256330,771326,397298,050271,439225,673229,5160000
       Goodwill 
266,397
264,730
324,351
282,408
282,683
271,319
834,541
578,354
582,171
578,521
578,443
578,479
578,479578,443578,521582,171578,354834,541271,319282,683282,408324,351264,730266,397
       Intangible Assets 
291,820
294,841
293,864
310,844
305,843
305,043
310,023
569,940
562,093
544,860
536,975
528,083
528,083536,975544,860562,093569,940310,023305,043305,843310,844293,864294,841291,820
> Total Liabilities 
914,541
907,135
924,953
961,430
945,877
880,344
1,586,959
1,592,124
1,614,095
1,615,625
1,585,783
1,650,672
1,650,6721,585,7831,615,6251,614,0951,592,1241,586,959880,344945,877961,430924,953907,135914,541
   > Total Current Liabilities 
160,830
155,613
169,569
227,913
212,057
217,792
294,433
300,282
337,952
394,489
414,271
439,583
439,583414,271394,489337,952300,282294,433217,792212,057227,913169,569155,613160,830
       Short Long Term Debt 
0
2,379
0
55,642
0
1,869
0
41,687
0
111,434
0
0
00111,434041,68701,869055,64202,3790
       Accounts payable 
52,014
52,101
60,080
53,150
56,022
56,100
80,405
76,935
85,985
86,641
105,390
93,174
93,174105,39086,64185,98576,93580,40556,10056,02253,15060,08052,10152,014
       Other Current Liabilities 
31,355
1,320
25,313
32,927
33,110
1,464
60,798
55,203
63,991
7,685
93,230
91,704
91,70493,2307,68563,99155,20360,7981,46433,11032,92725,3131,32031,355
   > Long-term Liabilities 
753,711
751,522
755,384
733,517
733,820
662,552
1,292,526
1,291,842
1,276,143
1,221,136
1,171,512
1,211,089
1,211,0891,171,5121,221,1361,276,1431,291,8421,292,526662,552733,820733,517755,384751,522753,711
       Capital Lease Obligations Min Short Term Debt
0
12,214
0
13,704
0
3,018
0
17,074
0
18,249
0
0
0018,249017,07403,018013,704012,2140
       Long-term Liabilities Other 
11,102
2,411
12,212
11,206
11,031
1,993
12,972
12,332
13,243
2,655
14,440
13,583
13,58314,4402,65513,24312,33212,9721,99311,03111,20612,2122,41111,102
> Total Stockholder Equity
423,201
497,316
534,085
452,994
503,863
531,592
580,563
521,201
545,891
539,207
581,906
551,556
551,556581,906539,207545,891521,201580,563531,592503,863452,994534,085497,316423,201
   Common Stock000000000000
   Retained Earnings 
266,306
337,954
375,325
273,011
325,466
355,357
404,762
345,073
369,917
367,223
410,842
380,731
380,731410,842367,223369,917345,073404,762355,357325,466273,011375,325337,954266,306
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 000000000000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,135,351
Cost of Revenue-416,191
Gross Profit719,160719,160
 
Operating Income (+$)
Gross Profit719,160
Operating Expense-955,250
Operating Income180,101-236,090
 
Operating Expense (+$)
Research Development10,628
Selling General Administrative95,283
Selling And Marketing Expenses0
Operating Expense955,250105,911
 
Net Interest Income (+$)
Interest Income2,494
Interest Expense-54,968
Other Finance Cost-17,260
Net Interest Income-69,734
 
Pretax Income (+$)
Operating Income180,101
Net Interest Income-69,734
Other Non-Operating Income Expenses0
Income Before Tax (EBT)105,997180,101
EBIT - interestExpense = -54,968
62,368
117,336
Interest Expense54,968
Earnings Before Interest and Taxes (EBIT)0160,965
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax105,997
Tax Provision-45,462
Net Income From Continuing Ops60,53460,535
Net Income62,368
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net069,734
 

Technical Analysis of Dermapharm Holding SE
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Dermapharm Holding SE. The general trend of Dermapharm Holding SE is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Dermapharm Holding SE's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Dermapharm Holding SE.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 37.94 < 38.43 < 38.43.

The bearish price targets are: 35.90 > 35.85 > 35.70.

Tweet this
Dermapharm Holding SE Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Dermapharm Holding SE. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Dermapharm Holding SE Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Dermapharm Holding SE.

Dermapharm Holding SE Daily Moving Average Convergence/Divergence (MACD) ChartDermapharm Holding SE Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Dermapharm Holding SE. The current adx is .

Dermapharm Holding SE Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Dermapharm Holding SE.

Dermapharm Holding SE Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Dermapharm Holding SE.

Dermapharm Holding SE Daily Relative Strength Index (RSI) ChartDermapharm Holding SE Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Dermapharm Holding SE.

Dermapharm Holding SE Daily Stochastic Oscillator ChartDermapharm Holding SE Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Dermapharm Holding SE.

Dermapharm Holding SE Daily Commodity Channel Index (CCI) ChartDermapharm Holding SE Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Dermapharm Holding SE.

Dermapharm Holding SE Daily Chande Momentum Oscillator (CMO) ChartDermapharm Holding SE Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Dermapharm Holding SE.

Dermapharm Holding SE Daily Williams %R ChartDermapharm Holding SE Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Dermapharm Holding SE.

Dermapharm Holding SE Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Dermapharm Holding SE.

Dermapharm Holding SE Daily Average True Range (ATR) ChartDermapharm Holding SE Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Dermapharm Holding SE.

Dermapharm Holding SE Daily On-Balance Volume (OBV) ChartDermapharm Holding SE Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Dermapharm Holding SE.

Dermapharm Holding SE Daily Money Flow Index (MFI) ChartDermapharm Holding SE Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Dermapharm Holding SE.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-17ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Dermapharm Holding SE Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Dermapharm Holding SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose36.000
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Dermapharm Holding SE with someone you think should read this too:
  • Are you bullish or bearish on Dermapharm Holding SE? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Dermapharm Holding SE? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Dermapharm Holding SE

I send you an email if I find something interesting about Dermapharm Holding SE.


Comments

How you think about this?

Leave a comment

Stay informed about Dermapharm Holding SE.

Receive notifications about Dermapharm Holding SE in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.